All In Biotech

Investigational drug · Phase 3

Plinabulin

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

15

Any phase or sponsor naming "Plinabulin"

First trial start

2026

Dec 1, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Plinabulin", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non-Small Cell Lung Cancer
  • Non-squamous Non-Small Cell Lung Cance

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Plinabulin" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 63 on PubMed

Also in development for Non-Small Cell Lung Cancer

  • SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials

    Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer

  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • AdebrelimabSHR-8068, HRS -4642Phase 341 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.